An Open-Label Three-Part Extension Study Assessing Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 19 Dec 2018
Price : $35 *
At a glance
- Drugs Levodopa/carbidopa (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors AbbVie
- 19 Dec 2018 Last checked against Japan Pharmaceutical Information Center - Clinical Trials Information record.
- 22 Mar 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Dec 2023.
- 06 Jan 2017 Planned number of patients changed from 37 to 31.